Market Place
Sourcing Support
Precigen Unveils 2025 Financials And Business Progress
25 Mar 2026 //
PR NEWSWIRE
New Expert Consensus In The Laryngoscope Endorses PAPZIMEOS
20 Jan 2026 //
PR NEWSWIRE
Precigen To Present At J.P. Morgan Healthcare Conference
05 Jan 2026 //
PR NEWSWIRE
Precigen Reports Q3 2025 Financial Results And Business Updates
13 Nov 2025 //
PR NEWSWIRE
Precigen Reports Q1 2025 Financial Results and Business Updates
14 May 2025 //
PR NEWSWIRE
Precigen Submits BLA with Priority Review Request for PRGN-2012
30 Dec 2024 //
PR NEWSWIRE
Precigen to Participate in the Stifel 2024 Healthcare Conference
12 Nov 2024 //
PR NEWSWIRE
Texas biotech axes cancer pact, pins hopes on obesity
11 Oct 2024 //
FIERCE BIOTECH
Precigen to Participate in the 2024 Cantor Global Healthcare Conference
16 Sep 2024 //
PR NEWSWIRE
Precigen Cuts 20% Staff, Pauses Programs To Fund Approval Filing
07 Aug 2024 //
FIERCE BIOTECH
Precigen Prioritizes Portfolio For First Potential Gene Therapy Launch
06 Aug 2024 //
PR NEWSWIRE
Precigen`s PRGN-2012 Shows Over 50% Complete Response In RRP
03 Jun 2024 //
PR NEWSWIRE
Precigen Prgn-2012 Papillomatosis: Pivotal Study Results Webcast Asco24
23 May 2024 //
PR NEWSWIRE
Precigen Reports First Quarter 2024 Financial Results and Business Updates
14 May 2024 //
PR NEWSWIRE
Precigen: Q1 2024 Financial Results Announcement and Conference Call
08 May 2024 //
PR NEWSWIRE
Precigen`s RRP Immunotherapy PRGN-2012 Data at ASCO 2024
24 Apr 2024 //
PR NEWSWIRE
Precigen Reports Full Year 2023 Financial Results and Business Updates
19 Mar 2024 //
PR NEWSWIRE
Precigen Highlights Pipeline Updates to be Presented
08 Jan 2024 //
PR NEWSWIRE
Precigen Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
PR NEWSWIRE
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse
20 Jun 2023 //
PR NEWSWIRE
ASCO 2023: Precigen reports positive early data for CAR-T therapy
06 Jun 2023 //
CLINICAL TRIALS ARENA
Precigen Announces Positive Phase 1 Data for PRGN-3005
05 Jun 2023 //
PR NEWSWIRE
Precigen Announces PI Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy
03 Jun 2023 //
PR NEWSWIRE
Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009
31 May 2023 //
PR NEWSWIRE
Precigen Reports First Quarter 2023 Financial Results and Business Updates
10 May 2023 //
PR NEWSWIRE
Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19/BCMA
04 Apr 2023 //
CONTRACT PHARMA
Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA
03 Apr 2023 //
PR NEWSWIRE
Precigen Announces Advancement of UltraCAR-T Platform
29 Mar 2023 //
PR NEWSWIRE
Precigen to Participate in Fireside Chat at "The Future of Oncology" Symposium
28 Mar 2023 //
PR NEWSWIRE
Precigen to Share Efficacy Data from PI Expansion Cohorts of PRGN-2012
04 Jan 2023 //
PR NEWSWIRE
